$SBRA
Sabra Health Care REIT, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149229824000031 Filed on October 31, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $178.0M
YoY Change 10.13%
Cost Of Revenue $54.23M
YoY Change 21.81%
Gross Profit $123.8M
YoY Change 5.69%
Gross Profit Margin 69.53%
Selling, General & Admin $12.26M
YoY Change 10.54%
% of Gross Profit 9.9%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $42.72M
YoY Change -1.21%
% of Gross Profit 34.52%
Operating Expenses $59.25M
YoY Change 1.05%
Operating Profit $64.52M
YoY Change 10.35%
Interest Expense -$29.25M
YoY Change 1.57%
% of Operating Profit -45.34%
Other Income/Expense, Net -$5.745M
YoY Change -87.04%
Pretax Income $29.31M
YoY Change -309.34%
Income Tax -$265.0K
% Of Pretax Income -0.9%
Net Earnings $29.79M
YoY Change -297.26%
Net Earnings / Revenue 16.73%
Basic Earnings Per Share $0.13
Diluted Earnings Per Share $0.13
COMMON SHARES
Basic Shares Outstanding 236.6M shares 234.3M shares
Diluted Shares Outstanding 237.0M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.00M
YoY Change 89.45%
Cash & Equivalents $63.00M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $177.3M
YoY Change -4.44%
LONG-TERM ASSETS
Property, Plant & Equipment $4.581B
YoY Change -0.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $130.8M
YoY Change -3.64%
Other Assets $5.972M
YoY Change 6.6%
Total Long-Term Assets $5.189B
YoY Change -0.12%
TOTAL ASSETS
Total Short-Term Assets $177.3M
Total Long-Term Assets $5.189B
Total Assets $5.366B
YoY Change -0.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $91.11M
YoY Change -14.81%
Accrued Expenses $31.70M
YoY Change 50.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $122.8M
YoY Change -4.09%
LONG-TERM LIABILITIES
Long-Term Debt $2.470B
YoY Change 5.14%
Other Long-Term Liabilities $28.27M
YoY Change -17.32%
Total Long-Term Liabilities $2.498B
YoY Change 4.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $122.8M
Total Long-Term Liabilities $2.498B
Total Liabilities $2.621B
YoY Change 4.36%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $2.366M
YoY Change 2.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.745B
YoY Change
Total Liabilities & Shareholders Equity $5.366B
YoY Change -0.27%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $29.79M
YoY Change -297.26%
Depreciation, Depletion And Amortization $42.72M
YoY Change -1.21%
Cash From Operating Activities $97.65M
YoY Change 17.35%
INVESTING ACTIVITIES
Capital Expenditures $76.10M
YoY Change
Acquisitions
YoY Change
Other Investing Activities $19.07M
YoY Change -68.18%
Cash From Investing Activities -$57.03M
YoY Change -195.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -13.95M
YoY Change -89.77%
NET CHANGE
Cash From Operating Activities 97.65M
Cash From Investing Activities -57.03M
Cash From Financing Activities -13.95M
Net Change In Cash 26.67M
YoY Change 295.04%
FREE CASH FLOW
Cash From Operating Activities $97.65M
Capital Expenditures $76.10M
Free Cash Flow $21.55M
YoY Change -74.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#HealthCareResidentServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#HealthCareResidentServiceMember
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 sbra Accounts Receivable Prepaid Expenses Deferred Financing Costs And Other Assets Net
AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
133806000 usd
CY2023Q4 us-gaap Assets
Assets
5386150000 usd
CY2023Q4 us-gaap Secured Debt
SecuredDebt
47301000 usd
CY2023Q4 us-gaap Line Of Credit
LineOfCredit
94429000 usd
CY2023Q4 us-gaap Loans Payable To Bank
LoansPayableToBank
537120000 usd
CY2023Q4 us-gaap Unsecured Debt
UnsecuredDebt
1735253000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
136981000 usd
CY2023Q4 us-gaap Below Market Lease Net
BelowMarketLeaseNet
32532000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2583616000 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
236586805 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
231266020 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2313000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4494755000 usd
CY2023Q4 us-gaap Accumulated Distributions In Excess Of Net Income
AccumulatedDistributionsInExcessOfNetIncome
1718279000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2802534000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5386150000 usd
CY2023Q3 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
8794000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
27746000 usd
us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
25991000 usd
CY2023Q3 us-gaap Revenues
Revenues
161627000 usd
us-gaap Revenues
Revenues
520889000 usd
us-gaap Revenues
Revenues
484117000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
43242000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
127315000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
140211000 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
28156000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
87189000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1541000 usd
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2229000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
838000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2570000 usd
CY2023Q3 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-46545000 usd
us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-3969000 usd
us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-75893000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-44316000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3131000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-74864000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
455000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
625000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1509000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15101000 usd
us-gaap Net Income Loss
NetIncomeLoss
80017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3400000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1347000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1226000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1948000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
8777000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6806000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
20606000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7671000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
73211000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17206000 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34981000 usd
CY2024Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2024Q3 us-gaap Dividends Common Stock
DividendsCommonStock
70798000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2744844000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3056395000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3400000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
20606000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7090000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-2138000 usd
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.90
us-gaap Dividends Common Stock
DividendsCommonStock
209700000 usd
us-gaap Net Income Loss
NetIncomeLoss
80017000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6806000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8180000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71825000 usd
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.90
us-gaap Dividends Common Stock
DividendsCommonStock
210906000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2744844000 usd
us-gaap Net Income Loss
NetIncomeLoss
80017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3400000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
140211000 usd
sbra Non Cash Rental And Related Revenues Adjustments
NonCashRentalAndRelatedRevenuesAdjustments
-6781000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
380000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8750000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9179000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6448000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5468000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1541000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-446000 usd
us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
39630000 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
21540000 usd
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
9614000 usd
sbra Payments For Preferred Equity Investments
PaymentsForPreferredEquityInvestments
2529000 usd
sbra Payments For Preferred Equity Investments
PaymentsForPreferredEquityInvestments
11015000 usd
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
39189000 usd
us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
63794000 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
0 usd
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
544000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-127561000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
164909000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
58815000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-165338000 usd
us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
0 usd
us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
12188000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68976000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38858000 usd
CY2024Q3 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1125470000 usd
CY2023Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1021086000 usd
CY2024Q3 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4574268000 usd
CY2023Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4617261000 usd
CY2024Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#HealthCareResidentServiceMember
dei Entity Registrant Name
EntityRegistrantName
SABRA HEALTH CARE REIT, INC.
CY2023Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1021086000 usd
CY2023Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4617261000 usd
CY2023Q4 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
420624000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
136843000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41285000 usd
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5434000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
30897000 usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23745000 usd
CY2023Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
93085000 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
285427000 usd
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
283229000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59748000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
174897000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
85024000 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14001000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
80943000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
245000 usd
CY2023Q3 sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
-645000 usd
sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
-301000 usd
sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
-2136000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15101000 usd
us-gaap Net Income Loss
NetIncomeLoss
80017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3400000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
22554000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7430000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
127315000 usd
sbra Non Cash Rental And Related Revenues Adjustments
NonCashRentalAndRelatedRevenuesAdjustments
-2229000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-24000 usd
us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-75893000 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
18472000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
87200000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9200000 usd
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
16500000 usd
sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
3640000 usd
sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
26426000 usd
CY2024Q3 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0 usd
CY2024Q3 us-gaap Derivative Collateral Obligation To Return Securities
DerivativeCollateralObligationToReturnSecurities
0 usd
CY2024Q3 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
0 usd
CY2024Q3 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
9708000 usd
CY2024Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
292000 usd
CY2024Q3 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2024Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
292000 usd
CY2024Q3 us-gaap Derivative Collateral Right To Reclaim Securities
DerivativeCollateralRightToReclaimSecurities
0 usd
CY2024Q3 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 usd
CY2024Q3 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
292000 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
18918000 usd
CY2023Q4 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0 usd
CY2023Q4 us-gaap Derivative Assets
DerivativeAssets
18918000 usd
CY2023Q4 us-gaap Derivative Collateral Obligation To Return Securities
DerivativeCollateralObligationToReturnSecurities
0 usd
CY2023Q4 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
0 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
18918000 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0 usd
CY2023Q4 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2024Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
CY2024Q3 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-5745000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
29788000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
80000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001492298
dei Entity Address City Or Town
EntityAddressCityOrTown
Tustin
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92782
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
393-8248
dei Trading Symbol
TradingSymbol
SBRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
236586805 shares
CY2024Q3 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1125470000 usd
CY2024Q3 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4574268000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
130811000 usd
CY2024Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5972000 usd
CY2024Q3 sbra Accounts Receivable Prepaid Expenses Deferred Financing Costs And Other Assets Net
AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
121456000 usd
CY2024Q3 us-gaap Assets
Assets
5366126000 usd
CY2024Q3 us-gaap Secured Debt
SecuredDebt
45817000 usd
CY2024Q3 us-gaap Line Of Credit
LineOfCredit
152558000 usd
CY2024Q3 us-gaap Loans Payable To Bank
LoansPayableToBank
535984000 usd
CY2024Q3 us-gaap Unsecured Debt
UnsecuredDebt
1735848000 usd
CY2024Q3 us-gaap Below Market Lease Net
BelowMarketLeaseNet
28270000 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
2366000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
16939000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5366126000 usd
CY2024Q3 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
94555000 usd
CY2024Q3 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
441825000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
122805000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73746000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
207716000 usd
CY2024Q3 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
9700000 usd
CY2024Q3 us-gaap Revenues
Revenues
178001000 usd
CY2024Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42720000 usd
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
29467000 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5745000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
29309000 usd
CY2024Q3 sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
214000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-265000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
29788000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2024Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-15148000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
15582000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2943744000 usd
CY2023Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2023Q3 us-gaap Dividends Common Stock
DividendsCommonStock
70030000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2868853000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2761975000 usd
CY2024Q3 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
9708000 usd
CY2024Q3 us-gaap Derivative Assets
DerivativeAssets
9708000 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#HealthCareResidentServiceMember
CY2023Q3 us-gaap Gain On Business Interruption Insurance Recovery Statement Of Income Or Comprehensive Income Extensible Enumeration
GainOnBusinessInterruptionInsuranceRecoveryStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNet
us-gaap Gain On Business Interruption Insurance Recovery Statement Of Income Or Comprehensive Income Extensible Enumeration
GainOnBusinessInterruptionInsuranceRecoveryStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2024#OtherOperatingIncomeExpenseNet
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://www.sabrahealth.com/20240930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2023Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://www.sabrahealth.com/20240930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2023Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2024Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2023Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2024#LineOfCredit http://fasb.org/us-gaap/2024#LoansPayableToBank
CY2023Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2024#LineOfCredit http://fasb.org/us-gaap/2024#LoansPayableToBank
CY2024Q3 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://www.sabrahealth.com/20240930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2024Q3 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://www.sabrahealth.com/20240930#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MD
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2560479
dei Entity Address Address Line1
EntityAddressAddressLine1
1781 Flight Way
dei Security12b Title
Security12bTitle
Common stock, $.01 par value
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63004000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28790000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
2621282000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
236586805 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
231266020 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4574707000 usd
CY2024Q3 us-gaap Accumulated Distributions In Excess Of Net Income
AccumulatedDistributionsInExcessOfNetIncome
1849168000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
2744844000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12404000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10759000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37035000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30793000 usd
CY2024Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-148000 usd
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
328000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-446000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
549000 usd
CY2024Q3 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 usd
CY2023Q3 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
18472000 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
7064000 usd
CY2024Q3 sbra Operating And Interest Expense
OperatingAndInterestExpense
142947000 usd
CY2023Q3 sbra Operating And Interest Expense
OperatingAndInterestExpense
131312000 usd
sbra Operating And Interest Expense
OperatingAndInterestExpense
436815000 usd
sbra Operating And Interest Expense
OperatingAndInterestExpense
409008000 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
234290187 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231224692 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232459388 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231197375 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
237043400 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231224692 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
234777101 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231197375 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
29788000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
942000 usd
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-5580000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14206000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15101000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7430000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2900000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-90000 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14206000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3104000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2868853000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2802534000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
549000 usd
us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-3969000 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
7064000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-301000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2136000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
3754000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1705000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-3704000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13589000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10660000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2213000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3013000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
230573000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
221834000 usd
us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
112225000 usd
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
2776000 usd
us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
8674000 usd
sbra Repayments Of Preferred Equity Investments
RepaymentsOfPreferredEquityInvestments
-5322000 usd
sbra Repayments Of Preferred Equity Investments
RepaymentsOfPreferredEquityInvestments
-4828000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
717000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
4797000 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
40541000 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
248222000 usd
us-gaap Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity
ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
0 usd
us-gaap Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity
ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
25490000 usd
us-gaap Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
0 usd
us-gaap Proceeds From Insurance Settlement Investing Activities
ProceedsFromInsuranceSettlementInvestingActivities
6001000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
1520000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
1479000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
18135000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
17900000 usd
sbra Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees
ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees
71362000 usd
sbra Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees
ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees
-2194000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
209174000 usd
us-gaap Payments Of Dividends
PaymentsOfDividends
208079000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-80597000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-400937000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22415000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14194000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-158000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-880000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46719000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53932000 usd
us-gaap Interest Paid Net
InterestPaidNet
71632000 usd
us-gaap Interest Paid Net
InterestPaidNet
72911000 usd
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0 usd
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
4644000 usd
CY2024Q3 sbra Real Estate Investments Joint Ventures Number
RealEstateInvestmentsJointVenturesNumber
0 investment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div>
CY2024Q3 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5699738000 usd
CY2024Q3 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1125470000 usd
CY2024Q3 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4574268000 usd
CY2023Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5638347000 usd
CY2023Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
1021086000 usd
CY2023Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4617261000 usd
CY2024Q3 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
4897747000 usd
CY2023Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
4843258000 usd
CY2024Q3 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
243226000 usd
CY2023Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
238185000 usd
CY2024Q3 us-gaap Land Improvements
LandImprovements
10919000 usd
CY2023Q4 us-gaap Land Improvements
LandImprovements
10306000 usd
CY2024Q3 us-gaap Land
Land
547846000 usd
CY2023Q4 us-gaap Land
Land
546598000 usd
CY2024Q3 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5699738000 usd
CY2023Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5638347000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000000 usd
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
130811000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
136843000 usd
sbra Disposal Group Including Discontinued Operations Number Of Properties
DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties
8 facility
sbra Disposal Group Including Discontinued Operations Number Of Properties
DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties
27 facility
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
40500000 usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
256200000 usd
CY2024Q3 sbra Disposal Group Including Discontinued Operation Assets And Liabilities Net
DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet
44500000 usd
CY2023Q3 sbra Disposal Group Including Discontinued Operation Assets And Liabilities Net
DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet
332100000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-4000000.0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-75900000 usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-8200000 usd
us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-79600000 usd
us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
5700000 usd
us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
7100000 usd
CY2024Q3 us-gaap Security Deposit Liability
SecurityDepositLiability
8700000 usd
CY2023Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
16400000 usd
CY2024Q3 sbra Letters Of Credit Deposits
LettersOfCreditDeposits
64000000 usd
CY2023Q4 sbra Letters Of Credit Deposits
LettersOfCreditDeposits
56000000 usd
CY2024Q3 sbra Property Taxes Insurance And Tenant Improvement Deposit Liability
PropertyTaxesInsuranceAndTenantImprovementDepositLiability
10800000 usd
CY2023Q4 sbra Property Taxes Insurance And Tenant Improvement Deposit Liability
PropertyTaxesInsuranceAndTenantImprovementDepositLiability
12400000 usd
CY2024Q3 us-gaap Variable Lease Income
VariableLeaseIncome
3500000 usd
us-gaap Variable Lease Income
VariableLeaseIncome
10000000.0 usd
CY2023Q3 us-gaap Variable Lease Income
VariableLeaseIncome
3800000 usd
us-gaap Variable Lease Income
VariableLeaseIncome
11400000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
92198000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
371685000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
358650000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
342012000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
319885000 usd
CY2024Q3 sbra Lessor Operating Lease Payment To Be Received After Year Four
LessorOperatingLeasePaymentToBeReceivedAfterYearFour
1422310000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
2906740000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7200000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11600000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8400000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
12500000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
294000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1518000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1032000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1047000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1021000 usd
CY2024Q3 sbra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
8938000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13850000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5454000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8396000 usd
CY2024Q3 sbra Financing Receivable Number Of Loans
FinancingReceivableNumberOfLoans
14 loan
CY2024Q3 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
391685000 usd
CY2024Q3 us-gaap Notes Receivable Gross
NotesReceivableGross
388236000 usd
CY2023Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
369440000 usd
CY2024Q3 sbra Financing Receivable Fixed Interest Rate
FinancingReceivableFixedInterestRate
0.078
CY2024Q3 sbra Financing Receivable Effective Interest Rate
FinancingReceivableEffectiveInterestRate
0.077
CY2024Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6219000 usd
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6665000 usd
CY2024Q3 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
391685000 usd
CY2024Q3 us-gaap Notes Receivable Net
NotesReceivableNet
382017000 usd
CY2023Q4 us-gaap Notes Receivable Net
NotesReceivableNet
362775000 usd
CY2024Q3 sbra Preferred Equity Investments Number
PreferredEquityInvestmentsNumber
5 preferredequityinvestment
CY2024Q3 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
59611000 usd
CY2024Q3 sbra Preferred Equity Investment Carrying Amount
PreferredEquityInvestmentCarryingAmount
59808000 usd
CY2023Q4 sbra Preferred Equity Investment Carrying Amount
PreferredEquityInvestmentCarryingAmount
57849000 usd
CY2024Q3 sbra Preferred Equity Investment Weighted Average Contractual Rate
PreferredEquityInvestmentWeightedAverageContractualRate
0.109
CY2024Q3 sbra Preferred Equity Investment Weighted Average Effective Rate
PreferredEquityInvestmentWeightedAverageEffectiveRate
0.109
CY2024Q3 sbra Number Of Investments
NumberOfInvestments
19 investment
CY2024Q3 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
451296000 usd
CY2024Q3 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
441825000 usd
CY2023Q4 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
420624000 usd
CY2024Q3 sbra Investments Weighted Average Contractual Rate
InvestmentsWeightedAverageContractualRate
0.082
CY2024Q3 sbra Investments Weighted Average Effective Rate
InvestmentsWeightedAverageEffectiveRate
0.081
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6665000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6611000 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
-446000 usd
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
549000 usd
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
0 usd
us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
483000 usd
CY2024Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6219000 usd
CY2023Q3 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6677000 usd
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
29500000 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
28200000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
85000000.0 usd
CY2024Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2600000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8800000 usd
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3100000 usd
CY2024Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
23300000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
513000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2089000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
502147000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
254764000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
543251000 usd
CY2024Q3 sbra Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1187402000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2490166000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
4826000 usd
CY2024Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
15133000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
2470207000 usd
CY2024Q3 sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
-15263000 usd
CY2023Q3 sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
15315000 usd
CY2023Q4 us-gaap Derivative Collateral Right To Reclaim Securities
DerivativeCollateralRightToReclaimSecurities
0 usd
CY2023Q4 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
0 usd
CY2024Q3 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
391685000 usd
CY2023Q4 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
372873000 usd
CY2024Q3 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
59611000 usd
CY2023Q4 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
57681000 usd
CY2024Q3 us-gaap Loans Receivable Fair Value Disclosure
LoansReceivableFairValueDisclosure
403673000 usd
CY2024Q3 sbra Preferred Equity Investment Fair Value Disclosure
PreferredEquityInvestmentFairValueDisclosure
61606000 usd
CY2024Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2024Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2024Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2000000.0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1400000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
29788000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15101000 usd
us-gaap Net Income Loss
NetIncomeLoss
80017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3400000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
234290187 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231224692 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232459388 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231197375 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2505456 shares
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2236433 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2024Q3 sbra Incremental Common Shares Attributable To Forward Equity Sale Agreements
IncrementalCommonSharesAttributableToForwardEquitySaleAgreements
247757 shares
CY2023Q3 sbra Incremental Common Shares Attributable To Forward Equity Sale Agreements
IncrementalCommonSharesAttributableToForwardEquitySaleAgreements
0 shares
sbra Incremental Common Shares Attributable To Forward Equity Sale Agreements
IncrementalCommonSharesAttributableToForwardEquitySaleAgreements
81280 shares
sbra Incremental Common Shares Attributable To Forward Equity Sale Agreements
IncrementalCommonSharesAttributableToForwardEquitySaleAgreements
0 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
237043400 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231224692 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
234777101 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231197375 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01

Files In Submission

Name View Source Status
0001492298-24-000031-index-headers.html Edgar Link pending
0001492298-24-000031-index.html Edgar Link pending
0001492298-24-000031.txt Edgar Link pending
0001492298-24-000031-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sbra-20240930.htm Edgar Link pending
sbra-20240930.xsd Edgar Link pending
sbraex3112024q3.htm Edgar Link pending
sbraex3122024q3.htm Edgar Link pending
sbraex3212024q3.htm Edgar Link pending
sbraex3222024q3.htm Edgar Link pending
Show.js Edgar Link pending
sbra-20240930_cal.xml Edgar Link unprocessable
sbra-20240930_def.xml Edgar Link unprocessable
sbra-20240930_lab.xml Edgar Link unprocessable
sbra-20240930_pre.xml Edgar Link unprocessable
sbra-20240930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable